ReviewEuropean respiratory review : an official journal of the European Respiratory Society2022
Diagnosis, course and management of hypersensitivity pneumonitis.
Review in European respiratory review : an official journal of the European Respiratory Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 123 citations in OpenAlex.
- Prognostic biomarkers for the development of progressive pulmonary fibrosis in hypersensitivity pneumonitis: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Diagnostic, prognostic, and therapeutic challenges in patients with hypersensitivity pneumonitis.ERJ open research · 2026Review
- Clinical Utility of an FDA-Authorized Artificial Intelligence Imaging Platform in Interstitial Lung Disease Diagnosis.Diagnostics (Basel, Switzerland) · 2026Article
- Acute inhalational lung injury caused by high-volume chlorhexidine spray.Internal and emergency medicine · 2026Article
- Quality of AI chatbot-generated information on hypersensitivity pneumonitis for clinical and patient use.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- Cutoffs for serum mold-specific IgG levels for hypersensitivity pneumonitis: a diagnostic test accuracy study of 219 subjects.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- Article
- Antibiotic-Induced Pulmonary Fibrosis: National Database Analysis.Biomedicines · 2026Article
- Current concepts in the diagnosis and treatment of hypersensitivity pneumonitis: a narrative review.Respiratory research & clinical practice · 2026Review
- Mechanisms of exercise limitation and prevalence of pulmonary hypertension in hypersensitivity pneumonitis.ERJ open research · 2026Article
- Case Report: Nebulized autologous platelet-rich plasma associated with quantitative CT and clinical changes in a patient with COPD and chronic hypersensitivity pneumonitis.Frontiers in medicine · 2026Article
- Upfront combination therapy with nintedanib and anti-inflammatory agents for progressive pulmonary fibrosis: a multicentre, single-arm phase 2 study (TOP-ILD).ERJ open research · 2026Article
- Article
- Biomarkers on Fibrotic Lung Diseases Associated with Usual Interstitial Pneumonia.International journal of medical sciences · 2026Review
- "Look What the Cat Dragged In": Delayed-Onset Hypersensitivity Pneumonitis Due to Pregnancy.Cureus · 2025Article
- Ethylbenzene Exposure and Bronchoalveolar CD4/CD8 T Cells in Hypersensitivity Pneumonitis Development and Clinical Outcome.Biomedicines · 2025Article
- From Hypersensitivity Pneumonitis to Lung Adenocarcinoma: A Case Report Illustrating Diagnostic Complexity.Cureus · 2025Article
- Drenched Pages: A Primer on Wet Books.Biology · 2025Review
- Korean Guidelines for the Diagnosis and Management of Interstitial Lung Diseases: Hypersensitivity Pneumonitis.Tuberculosis and respiratory diseases · 2025Article
- Fibrotic Hypersensitivity Pneumonitis: A Diagnostic Challenge Leading to Lung Transplantation.Diagnostics (Basel, Switzerland) · 2025Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypersensitivity pneumonitis (HP) is a complex and heterogeneous interstitial lung disease (ILD) that occurs when susceptible individuals develop an exaggerated immune response to an inhaled antigen. In this review, we discuss the latest guidelines for the diagnostic evaluation of patients with suspected HP, the importance of identifying patients with fibrotic and progressive disease, and the evidence supporting the drugs commonly used in the treatment of HP. Differential diagnosis of HP can be challenging and requires a thorough exposure history, multidisciplinary discussion of clinical and radiologic data, and, in some cases, assessment of bronchoalveolar lavage lymphocytosis and histopathologic findings. Patients with HP may be categorised as having non-fibrotic or fibrotic HP. The presence of fibrosis is associated with worse outcomes. A proportion of patients with fibrotic HP develop a progressive phenotype, characterised by worsening fibrosis, decline in lung function and early mortality. There are no established guidelines for the treatment of HP. Antigen avoidance should be implemented wherever possible. Immunosuppressants are commonly used in patients with HP but have not been shown to slow the worsening of fibrotic disease. Nintedanib, a tyrosine kinase inhibitor, has been approved by the US Food and Drug Administration for slowing the progression of chronic fibrosing ILDs with a progressive phenotype, including progressive fibrotic HP. Non-pharmacological interventions, such as oxygen therapy, pulmonary rehabilitation and supportive care, may be important components of the overall care of patients with progressive HP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.